1. SAT0169 Maintenance and improvement in clinical efficacy between week 12 and 24 in patients with rheumatoid arthritis treated with sb4 or reference etanercept. (15th June 2017) Authors: Emery, P; Vencovsky, J; Keystone, E; Ghil, J; Cheong, SY; Hong, EE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0204 Impact of anti-drug antibody and injection site reaction on efficacy: 24-week results from a phase iii study comparing SB4 (etanercept biosimilar) with reference etanercept in patients with rheumatoid arthritis. (15th June 2017) Authors: Vencovsky, J; Emery, P; Keystone, E; Ghil, J; Cheong, SY; Hong, EE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis. (15th June 2017) Authors: Kay, J; Weinblatt, M; Keystone, E; Genovese, M; Ghil, J; Cheong, SY; Hong, EE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗